Abstracts tagged "cutaneous lupus erythematosus and systemic lupus erythematosus (SLE)"

Abstract Number: 33 • 2017 ACR/ARHP Annual Meeting
B Cell Abnormalities in Patients with Chronic Cutaneous Lupus Erythematosus
Chungwen Wei¹, Aisha Hill², Kira Smith³, Ignacio Sanz¹, S. Sam Lim⁴ and Cristina Drenkard⁴, ¹Medicine, Emory University School of Medicine, Atlanta, GA, ²Medicine, Emory University School of Medicine, atlanta, GA, ³Emory University School of Medicine, Atlanta, GA, ⁴Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Lupus is a spectrum of disease with cutaneous lupus (CLE) without systemic features on one end and systemic lupus erythematosus (SLE) on the other.…
Abstract Number: 787 • 2016 ACR/ARHP Annual Meeting
Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus
Jenna K. Presto^1,2, Jessica S. Haber^1,2 and Victoria P. Werth^1,2, ¹Department of Dermatology, University of Pennsylvania, Philadelphia, PA, ²Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Discoid lupus erythematosus (DLE) progresses to systemic lupus erythematosus (SLE) in up to 28% of cases. The Systemic Lupus International Collaborating Clinics (SLICC) SLE…
Abstract Number: 2909 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis of Cutaneous Manifestations in Late Versus Early-Onset Systemic Lupus Erythematosus
Jennifer Medlin¹, Karen E. Hansen², Sara Fitz³ and Christie M. Bartels⁴, ¹Internal Medicine, University of Wisconsin Hospitals and Clinics, Madison, WI, ²Rheumatology/Medicine, Univ of Wisconsin, Madison, WI, ³Department of Dermatology, Mercy Medical Center, Dubuque, IA, ⁴Medicine, Rheumatology, University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Systemic lupus erythematosus (SLE) is commonly diagnosed in females of reproductive age, with those diagnosed after the age of 50 referred to as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].